Cholesteatoma - Complications Complications | Background information | Cholesteatoma | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1. NICE 2. CKS 3. Health topics A to Z 4. Cholesteatoma 5. Background information 6. Complications Cholesteatoma: What are the complications?Last revised in August 2024 Complications * Summary * Have I got the right topic? * How up-to-date is this topic? * Goals and outcome measures * Background information * Definition * Causes * Risk factors * Prevalence * Prognosis * Complications
Cholesteatoma - Prognosis Prognosis | Background information | Cholesteatoma | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1. NICE 2. CKS 3. Health topics A to Z 4. Cholesteatoma 5. Background information 6. Prognosis Cholesteatoma: What is the prognosis?Last revised in August 2024 Prognosis * Summary * Have I got the right topic? * How up-to-date is this topic? * Goals and outcome measures * Background information * Definition * Causes * Risk factors * Prevalence * Prognosis * Complications * Diagnosis * Management
Cholesteatoma - Definition Definition | Background information | Cholesteatoma | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1. NICE 2. CKS 3. Health topics A to Z 4. Cholesteatoma 5. Background information 6. Definition Cholesteatoma: What is it?Last revised in August 2024 Definition * Summary * Have I got the right topic? * How up-to-date is this topic? * Goals and outcome measures * Background information * Definition * Causes * Risk factors * Prevalence * Prognosis * Complications * Diagnosis * Management
Cholesteatoma - Assessment Assessment | Diagnosis | Cholesteatoma | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1 . NICE 2. CKS 3. Health topics A to Z 4. Cholesteatoma 5. Diagnosis 6. Assessment Cholesteatoma: How should I assess a person with suspected cholesteatoma?Last revised in August 2024 Assessment * Summary * Have I got the right topic? * How up-to-date is this topic? * Goals and outcome measures * Background information * Diagnosis * Diagnosis * Assessment * Differential diagnosis * Management
Cholesteatoma - Causes Causes | Background information | Cholesteatoma | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1. NICE 2. CKS 3. Health topics A to Z 4. Cholesteatoma 5. Background information 6. Causes Cholesteatoma: What causes it?Last revised in August 2024 Causes * Summary * Have I got the right topic? * How up-to-date is this topic? * Goals and outcome measures * Background information * Definition * Causes * Risk factors * Prevalence * Prognosis * Complications * Diagnosis * Management * Supporting
Cholesteatoma - Differential diagnosis Differential diagnosis | Diagnosis | Cholesteatoma | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1. NICE 2. CKS 3. Health topics A to Z 4. Cholesteatoma 5. Diagnosis 6. Differential diagnosis Cholesteatoma: What else might it be?Last revised in August 2024 Differential diagnosis * Summary * Have I got the right topic? * How up-to-date is this topic? * Goals and outcome measures * Background information * Diagnosis * Diagnosis * Assessment * Differential diagnosis
Cholesteatoma - Risk factors Risk factors | Background information | Cholesteatoma | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1. NICE 2. CKS 3. Health topics A to Z 4. Cholesteatoma 5. Background information 6. Risk factors Cholesteatoma: What are the risk factors?Last revised in August 2024 Risk factors * Summary * Have I got the right topic? * How up-to-date is this topic? * Goals and outcome measures * Background information * Definition * Causes * Risk factors * Prevalence * Prognosis * Complications
Cholesteatoma - Prevalence Prevalence | Background information | Cholesteatoma | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1. NICE 2. CKS 3. Health topics A to Z 4. Cholesteatoma 5. Background information 6. Prevalence Cholesteatoma: How common is it?Last revised in August 2024 Prevalence * Summary * Have I got the right topic? * How up-to-date is this topic? * Goals and outcome measures * Background information * Definition * Causes * Risk factors * Prevalence * Prognosis * Complications * Diagnosis
Cholesteatoma CKS is only available in the UK | NICE CKS is only available in the UKThe NICE Clinical Knowledge Summaries (CKS) site is only available to users in the UK, Crown Dependencies and British Overseas Territories.CKS content is produced by Clarity Informatics Limited. It is available to users outside the UK via subscription from the Prodigy website.If you believe you are seeing
Surgical Results of Canalplasty Using a Pedicled Periosteal Flap for External Auditory Canal Cholesteatoma. We evaluated the outcomes of canalplasty for external auditory canal cholesteatoma (EACC) using an inferior-pedicled periosteal flap to cover the eradicated diseased bone. Retrospective chart review. Tertiary referral center. Thirty-one ears in 30 patients surgically treated for stages III
Outcomes of Primary Acquired Cholesteatoma Managed with Endoscopic-Microscopic Approaches According to EAONO-JOS and SAMEO-ATO Classifications. To assess the utility of the European Academy of Otology and Neurotology-Japanese Otological Society (EAONO-JOS) and SAMEO-ATO tympanomastoid surgery classification systems in predicting recidivistic disease in patients with primary acquired cholesteatoma and to compare outcomes between endoscopic and combined approaches. Retrospective chart review. Academic teaching hospital. Eighty-one surgical ears from 77 patients were operated on between 2015 and 2022 by the senior author and fit the inclusion criteria. Surgeries were retrospectively classified according to SAMEO-ATO and EAONO-JOS classifications. Descriptive statistics for staging
Unique Cell Type-Specific Signaling Patterns Define Cholesteatoma. To identify cell types and signaling pathways that drive cholesteatoma. Single-cell RNA sequencing (scRNA-seq) was applied to identify differences between human cholesteatoma specimens and previously published scRNA-seq data for normal human tympanic membrane. The CellChat algorithm determined differential signaling pathways between both tissues. Cholesteatoma-specific markers were validated utilizing immunohistochemistry on human cholesteatoma specimens. Cholesteatoma is a complex, expansile, and destructive cystic epithelial lesion that occurs within the temporal bone. It destroys surrounding tissue, leading to significant otologic complications. Currently, the only treatment option is surgical removal of the disease
Prevalence of cholesteatoma in children with 22q11.2 deletion syndrome. To investigate the prevalence and relative risk of middle ear cholesteatoma in children with 22q11.2 deletion syndrome (22q11.2DS) as compared to children without the deletion, and to examine the relationship between cleft palate and cholesteatoma risk for these patients. A retrospective cohort study was conducted using the TriNetX Analytics Network, a federated health research network that aggregates data from 45 U S. healthcare organizations. Patients who are 18 years old or younger with 22q11.2DS and without 22q11.2DS (control) were included. Patients in each group with a diagnosis of middle ear cholesteatoma or cleft palate were reported. The study included 6883 children with 22q11.2DS and 18,678,712 children without
Whole exome sequencing study identifies candidate loss of function variants and locus heterogeneity in familial cholesteatoma. Cholesteatoma is a rare progressive disease of the middle ear. Most cases are sporadic, but some patients report a positive family history. Identifying functionally important gene variants associated with this disease has the potential to uncover the molecular basis of cholesteatoma pathology with implications for disease prevention, surveillance, or management. We performed an observational WES study of 21 individuals treated for cholesteatoma who were recruited from ten multiply affected families. These family studies were complemented with gene-level mutational burden analysis. We also applied functional enrichment analyses to identify shared properties and pathways
CholesteatomaCholesteatoma - Symptoms, diagnosis and treatment | BMJ Best PracticeSkip to main contentSkip to search * About us * Help * Subscribe * Access through your institution * Log inBMJ Best Practice * Help * Getting started * FAQs * Contact us * Recent updates * Specialties * Calculators * Patient leaflets * Videos * Evidence * Drugs * Recent updates * Specialties independent growth, leading to expansion and to resorption of underlying bone.[2]Lesser TH. Cholesteatoma. In: Roland NJ, McRae RD, McCombe AW, eds. Key topics in otolaryngology. 2nd ed. Informa Healthcare; 2001:35-37. Focal erosion of external canal bone with accumulation of keratin is called external canal cholesteatoma.[3]Heilbrun ME, Salzman KL, Glastonbury CM, et al. External auditory canal
Cost-Effectiveness of Diffusion Weighted MRI Versus Planned Second-Look Surgery for Cholesteatoma. To compare the cost-effectiveness of serial non-echo planar diffusion weighted MRI (non-EP DW MRI) versus planned second look surgery following initial canal wall up tympanomastoidectomy for the treatment of cholesteatoma. A decision-analytic model was developed. Model inputs including residual cholesteatoma rates, rates of non-EP DW MRI positivity after surgery, and health utility scores were abstracted from published literature. Cost data were derived from the 2022 Centers for Medicare and Medicaid Services fee rates. Efficacy was defined as increase in quality-adjusted life year (QALY). One- and 2-way sensitivity analyses were performed on variables of interest to probe the model. Total time
Selection of a Surgical Approach for Middle Ear Cholesteatoma Based on the Fusion Images of Non-Echo Planar Diffusion-Weighted MRI and CT. This study aimed to explore the ability of fusion images of non-echo planar diffusion-weighted magnetic resonance imaging (non-EPI-DWI MRI) and computed tomography (CT) to accurately locate cholesteatoma and plan the surgical approach. In the first part, 41 patients were included. Their CT images and non-EPI DWMRI images were fused. The scope of cholesteatoma in the fusion image was compared with that in the surgical video to evaluate the capability to locate cholesteatoma. A total of 229 patients were included in the second part, and they were divided into 2 groups. We chose the surgical approach for the CT group and the fusion group, and compared
Post-operative vestibular and equilibrium evaluation in patients with cholesteatoma-induced labyrinthine fistulas. This study aimed to compare the pre- and post-operative vestibular and equilibrium functions of patients with cholesteatoma-induced labyrinthine fistulas who underwent different management methods. Data from 49 patients with cholesteatoma-induced labyrinthine fistulas who underwent in the obliteration group. Despite receiving different management strategies, all patients achieved complete recovery of equilibrium functions through persistent efforts in rehabilitation exercises. Complete removal of the cholesteatoma matrix overlying the fistula is reliable for preventing iatrogenic hearing deterioration due to unremitting labyrinthitis. Thus, among the three fistula treatments, obliteration
Cost-Effectiveness of Diffusion-Weighted Magnetic Resonance Imaging Versus Second-Look Surgery in Treating Cholesteatoma: A Modeling Study. To evaluate whether canal wall-up (CWU) tympanomastoidectomy with diffusion-weighted magnetic resonance imaging (DW-MRI) is a cost-effective method of treating cholesteatoma compared with CWU with second-look surgery. Cost-effectiveness analysis -effective approach 63.7% of the time by simulation. Both treatment pathways were found to be cost-effective, with second-look surgery incrementally cost-effective 63.7% of the time. Assumptions were validated by one-way and Monte Carlo probability sensitivity analysis. There is ample variation in treatment pathways regarding usage of DW-MRI and second-look surgery for cholesteatoma. To evaluate the cost
Ectodermal dysplasia and cholesteatoma: A cross-sectional analysis of otologic issues. Previous studies have also associated cleft palate with increased cholesteatoma risk. Despite this close relation, the incidence of cholesteatoma and associated otologic issues in patients with ectodermal dysplasia types highly associated with cleft palate (EDT-ACPs) has not been formally analyzed. This study individuals participated in the survey (response rate approx. 18 %). The median [IQR] age was 22 [14, 43], 41 (63 %) were female, and Ectrodactyly-Ectodermal Dysplasia-Cleft Lip/Palate Syndrome (EEC) was most common (n = 26, 40 %). We found that, among our respondents with a history of cleft palate, the incidence of cholesteatoma was 39 %. Among respondents without a history of cleft palate, the incidence